Anemia Sel Sabit

01Pathophysiology

Sickle cell anemia (HbSS) results from a single nucleotide substitution in the beta-globin gene on chromosome 11. The sixth amino acid of the beta-globin chain is changed from glutamic acid (hydrophilic) to valine (hydrophobic). This substitution produces hemoglobin S (HbS). Under conditions of low oxygen tension, dehydration, acidosis, or temperature extremes, HbS molecules polymerize into rigid, rod-like fibers. These fibers distort the red blood cell into the characteristic crescent or "sickle" shape.

The sickling process has two principal downstream consequences. First, sickled RBCs are rigid and poorly deformable, so they obstruct small blood vessels. This vaso-occlusion causes tissue ischemia and infarction, which is the basis for pain crises, acute chest syndrome, stroke, dactylitis, splenic infarction, avascular necrosis, and priapism. Second, sickled cells have a markedly shortened lifespan (approximately 10 to 20 days instead of the normal 120 days), leading to chronic extravascular and intravascular hemolysis. This hemolysis drives the chronic anemia, jaundice, elevated indirect bilirubin, elevated LDH, low haptoglobin, reticulocytosis, and pigmented (bilirubin) gallstones commonly seen in these patients.

There is also a critical interplay between sickling and the endothelium. Free hemoglobin released during hemolysis scavenges nitric oxide (NO), a vasodilator. The resulting NO depletion promotes vasoconstriction, platelet aggregation, and endothelial adhesion of sickled cells, worsening vaso-occlusion. This creates a vicious cycle: sickling causes hemolysis, hemolysis depletes NO, NO depletion worsens vasoconstriction, and vasoconstriction promotes more sickling.

Functional asplenia develops because recurrent splenic infarctions from sickled cells progressively destroy the spleen, typically by age 5. This renders the patient highly susceptible to infections by encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis). Overwhelming post-splenectomy-like sepsis is a leading cause of death in young children with sickle cell disease, which is why prophylactic penicillin is started at birth.

An important protective note: sickle cell trait (HbAS) confers resistance to Plasmodium falciparum malaria, which explains the high prevalence of the HbS allele in malaria-endemic regions. Trait carriers are generally asymptomatic under normal physiologic conditions but may sickle under extreme hypoxia (e.g., unpressurized high-altitude flight, intense exertion).

02Classification and Clinical Manifestation

Genotypes

Acute Complications (Crisis Types)

Chronic Complications

03Diagnostic Workup

Hemoglobin electrophoresis is the best initial and confirmatory diagnostic test. In most developed countries, this is performed as part of universal newborn screening. The characteristic finding in HbSS disease is a predominance of HbS (approximately 80 to 90%), elevated fetal hemoglobin (HbF, approximately 2 to 20%), the presence of HbA2, and the complete absence of HbA. In sickle cell trait (HbAS), both HbA and HbS are present, with HbA predominating.

The peripheral blood smear provides critical supporting evidence. You will see irreversibly sickled cells (crescent or boat-shaped), target cells, and Howell-Jolly bodies. The Howell-Jolly bodies are nuclear remnants that persist because the spleen, which normally removes them, is no longer functional. Their presence on a smear is essentially a marker of functional asplenia.

The reticulocyte count is a high-yield test for differentiating between crisis types. In the baseline state and during vaso-occlusive or hemolytic crises, the reticulocyte count is elevated (the marrow is compensating). In an aplastic crisis triggered by parvovirus B19, the reticulocyte count drops dramatically toward zero because the virus directly infects erythroid precursors and halts red cell production. This distinction (high vs. absent reticulocytes) is one of the most commonly tested differentiators.

Transcranial Doppler (TCD) ultrasonography is recommended annually for children with HbSS from ages 2 through 16 to screen for stroke risk. A time-averaged mean velocity exceeding 200 cm/s in the middle cerebral or internal carotid artery identifies children at high risk who benefit from chronic transfusion therapy to maintain HbS below 30%.

04Management and Treatment

Hydroxyurea is the cornerstone of chronic management and should be offered to all patients with HbSS disease, starting as early as 9 months of age regardless of clinical severity. It works by increasing fetal hemoglobin (HbF) production, which inhibits HbS polymerization. Additional benefits include reducing white blood cell and platelet counts (decreasing endothelial adhesion), improving RBC hydration, and releasing nitric oxide. The typical starting dose is 15 mg/kg/day, titrated upward to a maximum of 35 mg/kg/day or the maximum tolerated dose. Monitoring with CBC every 4 to 8 weeks during dose escalation is required to watch for myelosuppression (primarily neutropenia). Hydroxyurea is teratogenic and contraindicated in pregnancy.

Penicillin V prophylaxis is initiated at birth or at the time of diagnosis, given the high risk of fatal pneumococcal sepsis in functionally asplenic children. The dose is 125 mg orally twice daily from birth to age 3, then increased to 250 mg twice daily from age 3 to at least age 5. Some guidelines recommend continuing prophylaxis indefinitely.

For vaso-occlusive crises, the treatment triad is aggressive IV hydration, analgesics, and supplemental oxygen if hypoxic. Pain management follows a stepwise approach: NSAIDs (ketorolac) for mild to moderate pain, and parenteral opioids (morphine or hydromorphone) for severe pain. Avoid meperidine (normeperidine accumulation causes seizures). Avoid excessive IV fluids, as this can precipitate acute chest syndrome.

Acute chest syndrome is the leading cause of death in adults with sickle cell disease and requires immediate, aggressive treatment. The standard approach includes broad-spectrum antibiotics covering both typical and atypical organisms (a third-generation cephalosporin plus a macrolide such as azithromycin), supplemental oxygen, incentive spirometry, bronchodilators, and transfusion. For severe or rapidly worsening acute chest syndrome (worsening hypoxia, multilobar infiltrates, declining hemoglobin), exchange transfusion is indicated to rapidly reduce the percentage of HbS below 30%.

For stroke, emergent exchange transfusion is the immediate intervention, targeting HbS below 30%. Following an initial stroke, patients are placed on a chronic transfusion program (simple transfusions every 3 to 4 weeks) to maintain HbS below 30% indefinitely, as the risk of recurrent stroke without chronic transfusion exceeds 60 to 70%. Iron overload from chronic transfusion is managed with iron chelation therapy (deferasirox).

Hematopoietic stem cell transplant (HSCT) remains the only curative therapy. It is most commonly performed in children with severe disease who have an HLA-matched sibling donor, with cure rates exceeding 90% in this population. Gene therapy approaches (including gene addition and gene editing strategies) are emerging as promising alternatives.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap in sickle cell disease questions is failing to distinguish between an aplastic crisis and a hemolytic crisis based on the reticulocyte count. Both present with worsening anemia, but the reticulocyte count tells the whole story. In an aplastic crisis (parvovirus B19), reticulocytes are absent because erythroid precursors are destroyed. In a hemolytic crisis, reticulocytes are markedly elevated because the bone marrow is compensating. When the vignette says "sudden severe anemia" and gives a reticulocyte count near zero, think parvovirus B19.

Another frequently tested concept is the organism responsible for osteomyelitis in sickle cell patients. In the general population, S. aureus is the most common cause. In SCD patients, the answer is Salmonella. S. aureus is still the second most common in SCD, but the expected answer when a sickle cell patient presents with bone infection is Salmonella.

Watch for questions about a child under 5 years with sickle cell disease presenting with sudden massive splenomegaly and cardiovascular collapse. This is splenic sequestration crisis, and the next best step is emergent volume resuscitation followed by RBC transfusion. This crisis is unique to young children because older children and adults have already undergone autosplenectomy.

On imaging, the "crew-cut" or "hair-on-end" appearance on skull X-ray results from expansion of the bone marrow cavity due to chronic extramedullary hematopoiesis. This finding also occurs in thalassemia major. The distinguishing factor is the hemoglobin electrophoresis pattern and the presence or absence of sickle cells on the smear.

A subtle but testable point involves acute chest syndrome: any sickle cell patient admitted for a vaso-occlusive crisis who develops new fever, chest pain, and a new infiltrate on chest radiograph has acute chest syndrome until proven otherwise. The vignette may start as a straightforward pain crisis and then evolve. Incentive spirometry is both a preventive and therapeutic measure during admissions for pain crises, specifically to prevent ACS.

Finally, remember that the only curative therapy is hematopoietic stem cell transplant. Hydroxyurea is the most important chronic disease-modifying agent, but it is not curative. When the question asks for the "only cure," the answer is HSCT.

The core competency tested across sickle cell disease questions is your ability to connect the pathophysiology (HbS polymerization, vaso-occlusion, hemolysis, functional asplenia) directly to each clinical complication, and then to select the correct next step in management based on which crisis type the vignette describes.